Prostamax (Prostamed Peptide)
Prostamax is a Khavinson-type peptide preparation marketed for prostate support, related to the registered prostate peptide bioregulator prostatilen/Vitaprost. Evidence is limited to Russian clinical use of the parent prostate extract; the marketed synthetic peptide lacks independent trials.
01 Overview
Prostamax is sold as a short prostate-targeting peptide bioregulator in the Khavinson tradition, positioned for benign prostatic hyperplasia and chronic prostatitis. The related registered product prostatilen (a prostate peptide extract) has Russian clinical use showing symptom improvement in prostatitis.\n\nThe specific marketed peptide has no independent, controlled human trials, and prostate symptoms warrant medical evaluation rather than self-treatment. Sold as a research peptide.
02 Mechanism
Proposed tissue-specific regulation of prostate gland function, reducing inflammation and edema; mechanism for the marketed peptide is unverified.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 5–10 mg/day | IM | Short cycled courses per vendor/Russian protocols. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Reduced prostatitis symptomsRelated prostate peptide extracts reduced symptoms in Russian prostatitis studies; marketed peptide unproven. | n/a | Observational | |
| Anti-inflammatory prostate effectProposed reduction of prostatic edema in animal models. | n/a | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Injection-site reactionLocal irritation at injection sites. | Mild | Common | Anecdotal | |
| Masking of serious prostate diseaseSelf-treating prostate symptoms may delay diagnosis of BPH complications or prostate cancer. | Moderate | Situational | Unconfirmed |